An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

NCT00608907 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Non-Hodgkin's Lymphoma

Interventions

DRUG: bortezomib
DRUG: bortezomib, rifampicin
DRUG: bortezomib, dexamethasone

Sponsor

Millennium Pharmaceuticals, Inc.

Collaborators

[object Object]